Physician profile
Shery Thomas
NPI 1467478388
$3,696.39
in general payments reported to CMS, 2019-2025
40 companies · $707 in 2025
The $707 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $329 · 2021: $276 · 2022: $469 · 2023: $549 · 2024: $880 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $470.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $392.77 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $388.47 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $363.72 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $239.66 | 2019-2025 | |
| Eisai INC. | $193.43 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.10 | 2020-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $179.51 | 2021-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $150.52 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $135.88 | 2019-2022 | |
| Abbvie INC. | $100.94 | 2023-2025 | Vraylar |
| Exact Sciences Corporation | $94.53 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $77.55 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.91 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $58.16 | 2023-2024 | Gemtesa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shery Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.